RIGEL PHARMACEUTICALS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($69.2m) ($78.0m) ($70.5m) ($66.9m) ($29.7m) ($17.9m) ($58.6m) ($25.1m) $17.5m $367.0m
Net Income (Loss) Available to Common Stockholders, Basic ($69.2m) ($78.0m) ($70.5m) ($66.9m) ($29.7m) ($17.9m) ($58.6m) ($25.1m) $17.5m $367.0m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($78.0m) ($70.5m) ($66.9m) ($29.7m) ($17.9m) ($58.6m) ($25.1m) $17.5m $367.0m
Depreciation, Depletion and Amortization $941k $465k $594k $683k $706k $1.2m $998k $1.2m $2.2m $2.4m
Amortization of Intangible Assets $100k $1.1m $2.1m $2.4m
Deferred Income Tax Expense (Benefit) $0 $0 ($245.9m)
Share-based Payment Arrangement, Noncash Expense $7.3m $6.0m $7.7m $9.1m $7.3m $9.5m $12.4m $8.8m $12.4m $12.7m
Share-based Payment Arrangement, Expense $7.8m $6.0m $7.7m $9.1m $7.3m $9.5m $12.4m $8.8m $12.4m $12.7m
Restructuring Costs and Asset Impairment Charges $319k $319k $100k
Gain (Loss) on Disposition of Assets $88k $732k ($138k) ($266k) $79k $0
Income Tax Expense (Benefit) $0 $0 $0 $605k $0 $881k ($245.2m)
Interest Expense Nonoperating $7.3m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable ($203k) $4.1m $6.0m $5.9m ($501k) $24.8m ($9.8m) $11.1m $10.1m
Increase (Decrease) in Inventories $839k $366k $126k $4.9m $2.4m ($1.2m) ($764k) $5.6m
Increase (Decrease) in Accounts Payable $2.8m ($2.9m) $3.8m ($2.2m) ($331k) $41k $3.8m ($366k) ($3.8m) $3.9m
Accretion Expense $2.8m $700k $700k
General and Administrative Expense $20.9m $37.8m
Investment Income, Interest $437k $892k $2.2m $2.5m $582k $47k $684k $2.3m $2.1m $3.7m
Net Cash Provided by (Used in) Operating Activities ($75.9m) ($77.6m) ($58.8m) ($41.5m) ($52.2m) $5.9m ($73.8m) ($5.7m) $31.5m $75.7m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $804k $164k $1.1m $1.5m $1.3m $627k $450k $0 $36k $0
Net Cash Provided by (Used in) Investing Activities $24.9m ($19.5m) $25.0m ($23.7m) $47.5m ($80.0m) $72.8m ($4.3m) $4.1m ($92.4m)
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $23.6m $114.2m $67.2m $1.6m $2.6m $4.8m $2.1m $1.0m $2.0m $8.1m
Net Cash Provided by (Used in) Financing Activities $25.2m $117.7m $71.9m $11.4m $12.6m $62.7m $6.5m $18.4m ($11.6m) $601k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20.7m $38.0m ($53.8m) $7.9m $18.9m $24.5m $32.8m $56.7m $40.6m
Cash, Cash Equivalents, and Short-term Investments $74.8m $115.8m $128.5m $98.1m $57.3m $125.0m $58.2m $56.9m $77.3m $155.0m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $137k $1.2m $1.5m $2.5m $5.8m $7.0m $6.6m
Income Taxes Paid, Net $81k $331k $1.1m